Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity
Thirteen new fluorine-containing drugs, which have been granted approval by the US Food
and Drug Administration (FDA) in 2020, are profiled in this review. Therapeutic areas of …
and Drug Administration (FDA) in 2020, are profiled in this review. Therapeutic areas of …
Oncogenic kinase signalling
P Blume-Jensen, T Hunter - Nature, 2001 - nature.com
Protein-tyrosine kinases (PTKs) are important regulators of intracellular signal-transduction
pathways mediating development and multicellular communication in metazoans. Their …
pathways mediating development and multicellular communication in metazoans. Their …
Genomic basis for coral resilience to climate change
Recent advances in DNA-sequencing technologies now allow for in-depth characterization
of the genomic stress responses of many organisms beyond model taxa. They are especially …
of the genomic stress responses of many organisms beyond model taxa. They are especially …
KIF5B-RET fusions in lung adenocarcinoma
T Kohno, H Ichikawa, Y Totoki, K Yasuda, M Hiramoto… - Nature medicine, 2012 - nature.com
We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET
oncogene, which are present in 1–2% of lung adenocarcinomas (LADCs) from people from …
oncogene, which are present in 1–2% of lung adenocarcinomas (LADCs) from people from …
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
S Kato, V Subbiah, E Marchlik, SK Elkin, JL Carter… - Clinical Cancer …, 2017 - AACR
Purpose: Aberrations in genetic sequences encoding the tyrosine kinase receptor RET lead
to oncogenic signaling that is targetable with anti-RET multikinase inhibitors. Understanding …
to oncogenic signaling that is targetable with anti-RET multikinase inhibitors. Understanding …
[HTML][HTML] Clinical and translational implications of RET rearrangements in non–small cell lung cancer
Since the discovery in 2012 of rearranged during transfection proto-oncogene gene (RET)
rearrangements in NSCLC, at least 12 different fusion variants have been identified, with …
rearrangements in NSCLC, at least 12 different fusion variants have been identified, with …
Tumor-agnostic precision medicine from the AACR GENIE database: clinical implications
Biomarker-driven cancer therapy has revolutionized precision oncology. With a better
understanding of tumor biology, tissue-agnostic targets have been characterized and …
understanding of tumor biology, tissue-agnostic targets have been characterized and …
Nuclear structure in cancer cells
D Zink, AH Fischer, JA Nickerson - Nature reviews cancer, 2004 - nature.com
Nuclear architecture—the spatial arrangement of chromosomes and other nuclear
components—provides a framework for organizing and regulating the diverse functional …
components—provides a framework for organizing and regulating the diverse functional …
[HTML][HTML] Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
K Okamoto, K Kodama, K Takase, NH Sugi… - Cancer letters, 2013 - Elsevier
RET gene fusions are recurrent oncogenes identified in thyroid and lung carcinomas.
Lenvatinib is a multi-tyrosine kinase inhibitor currently under evaluation in several clinical …
Lenvatinib is a multi-tyrosine kinase inhibitor currently under evaluation in several clinical …
[HTML][HTML] Regulation of MAPKs by growth factors and receptor tyrosine kinases
Multiple growth-and differentiation-inducing polypeptide factors bind to and activate
transmembrane receptors tyrosine kinases (RTKs), to instigate a plethora of biochemical …
transmembrane receptors tyrosine kinases (RTKs), to instigate a plethora of biochemical …